PET/MR Imaging: A Critical Appraisal
- 12 May 2014
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 55 (Supplement) , 56S-58S
Abstract
Despite considerable excitement about the potential of PET/MR imaging for the detection, staging, and functional characterization of cancer, this new technology is evolving significantly more slowly than PET/CT. This slower evolution is due partly to ongoing technologic challenges (e.g., accurate attenuation correction of PET images) but also to the complex logistics of combining a whole-body PET scan with whole-body or organ-specific MR imaging. Most PET/MR imaging research published so far has focused on cancer staging and restaging in patients undergoing 18F-FDG PET/CT as the standard of care. These studies have demonstrated the feasibility of clinical 18F-FDG PET/MR imaging but so far have not shown substantial improvements in staging. This situation may not be unexpected in view of the fact that MR imaging has not replaced CT for staging of the malignancies for which 18F-FDG PET/CT is most commonly used. Given the widespread concerns about rising health care costs in general and the costs of advanced imaging techniques in particular, establishing 18F-FDG PET/MR imaging for whole-body cancer staging may be challenging because it requires more expensive equipment and longer acquisition times than 18F-FDG PET/CT. An alternative approach to developing clinical PET/MR imaging is to study how stand-alone, organ-specific MR imaging can be improved by PET/MR imaging. Unfortunately, however, 18F-FDG PET has significant limitations for the tumors that are most commonly studied with MR imaging (brain, liver, pancreatic, and prostate tumors). However, this situation may change with the development of new radiopharmaceuticals, such as prostate-specific membrane or gastrin-releasing peptide receptor ligands for the imaging of prostate cancer. In conclusion, PET/MR imaging has many potential advantages over PET/CT (lower radiation exposure, higher soft-tissue contrast, and multiparametric imaging). Realizing this potential in clinics likely will require new radiopharmaceuticals and applications other than whole-body cancer staging.Keywords
This publication has 30 references indexed in Scilit:
- Baseline 18F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate CancerJournal of Nuclear Medicine, 2013
- Is There Evidence for Evidence-Based Medical Imaging?: TABLE 1Journal of Nuclear Medicine, 2011
- Doing More Harm than Good? Do Systematic Reviews of PET by Health Technology Assessment Agencies Provide an Appraisal of the Evidence That Is Closer to the Truth than the Primary Data Supporting Its Use?Journal of Nuclear Medicine, 2011
- Generating Evidence for Clinical Benefit of PET/CT in Diagnosing Cancer PatientsJournal of Nuclear Medicine, 2011
- Contribution of Imaging to Cancer Care CostsJournal of Nuclear Medicine, 2011
- Delivering affordable cancer care in high-income countriesThe Lancet Oncology, 2011
- Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate CancerClinical Cancer Research, 2010
- Detection of Hepatocellular Carcinoma with PET/CT: A Prospective Comparison of18F-Fluorocholine and18F-FDG in Patients with Cirrhosis or Chronic Liver DiseaseJournal of Nuclear Medicine, 2010
- Health Insurers and Medical-Imaging Policy — A Work in ProgressNew England Journal of Medicine, 2009
- L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005